ALLO
Price
$2.85
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
14 days until earnings call
LXRX
Price
$1.91
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
20 days until earnings call
Ad is loading...

ALLO vs LXRX

Header iconALLO vs LXRX Comparison
Open Charts ALLO vs LXRXBanner chart's image
Allogene Therapeutics
Price$2.85
Change-$0.00 (-0.00%)
Volume$1.31M
CapitalizationN/A
Lexicon Pharmaceuticals
Price$1.91
Change-$0.00 (-0.00%)
Volume$3.19M
CapitalizationN/A
View a ticker or compare two or three
ALLO vs LXRX Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ALLO vs. LXRX commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and LXRX is a Buy.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (ALLO: $2.85 vs. LXRX: $1.91)
Brand notoriety: ALLO and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 73% vs. LXRX: 120%
Market capitalization -- ALLO: $608.51M vs. LXRX: $567.54M
ALLO [@Biotechnology] is valued at $608.51M. LXRX’s [@Biotechnology] market capitalization is $567.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileLXRX’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, LXRX is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 6 TA indicator(s) are bullish while LXRX’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 6 bullish, 3 bearish.
  • LXRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than LXRX.

Price Growth

ALLO (@Biotechnology) experienced а +7.95% price change this week, while LXRX (@Biotechnology) price change was +17.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

ALLO is expected to report earnings on Feb 26, 2025.

LXRX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($609M) has a higher market cap than LXRX($568M). LXRX YTD gains are higher at: 24.837 vs. ALLO (-11.215). LXRX has higher annual earnings (EBITDA): -185.05M vs. ALLO (-256.56M). ALLO has more cash in the bank: 445M vs. LXRX (310M). ALLO has less debt than LXRX: ALLO (87M) vs LXRX (101M). LXRX has higher revenues than ALLO: LXRX (3.64M) vs ALLO (65K).
ALLOLXRXALLO / LXRX
Capitalization609M568M107%
EBITDA-256.56M-185.05M139%
Gain YTD-11.21524.837-45%
P/E RatioN/AN/A-
Revenue65K3.64M2%
Total Cash445M310M144%
Total Debt87M101M86%
FUNDAMENTALS RATINGS
ALLO vs LXRX: Fundamental Ratings
ALLO
LXRX
OUTLOOK RATING
1..100
1320
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
8152
P/E GROWTH RATING
1..100
10034
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LXRX's Valuation (67) in the Biotechnology industry is in the same range as ALLO (97). This means that LXRX’s stock grew similarly to ALLO’s over the last 12 months.

LXRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that LXRX’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (96) in the Biotechnology industry is in the same range as LXRX (98). This means that ALLO’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (52) in the Biotechnology industry is in the same range as ALLO (81). This means that LXRX’s stock grew similarly to ALLO’s over the last 12 months.

LXRX's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that LXRX’s stock grew significantly faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOLXRX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 23 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME21.660.39
+1.83%
GameStop Corp
BTC.X67612.720000571.609400
+0.85%
Bitcoin cryptocurrency
TSLA221.331.76
+0.80%
Tesla
SPY582.302.52
+0.43%
SPDR® S&P 500® ETF Trust
AAPL231.78-2.07
-0.89%
Apple

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with NTLA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+5.17%
NTLA - ALLO
60%
Loosely correlated
+5.43%
EDIT - ALLO
55%
Loosely correlated
+2.68%
CRSP - ALLO
55%
Loosely correlated
+1.98%
PRME - ALLO
55%
Loosely correlated
+5.04%
BEAM - ALLO
54%
Loosely correlated
+1.33%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with NTLA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+6.70%
NTLA - LXRX
52%
Loosely correlated
+5.43%
ABCL - LXRX
51%
Loosely correlated
+2.34%
BEAM - LXRX
50%
Loosely correlated
+1.33%
ADPT - LXRX
48%
Loosely correlated
-3.42%
ALLO - LXRX
48%
Loosely correlated
+5.17%
More